SciSparc (SPRC) Net Income (2016 - 2022)

SciSparc (SPRC) posted Net Income of -$359000.0 for Q4 2022, down 113.14% sequentially from $2.7 million in Q3 2022.

SciSparc (SPRC) Net Income (2016 - 2022) Analysis & Trends

SciSparc has reported Net Income for 5 years, with the latest figure at -$359000.0 in Q4 2022.

Quarterly Net Income changed N/A year-over-year to -$359000.0 in Q4 2022, while the trailing twelve-month figure through Jun 2024 was -$359000.0 (down 115.13% YoY) and the FY2025 annual result came in at -$12.6 million, down 268.15% from the prior year.
Net Income slipped to -$359000.0 in Q4 2022 per SPRC's latest filing, from $2.7 million in the prior quarter.
Over five years, Net Income peaked at $14.0 million in Q4 2018 and troughed at -$1.7 million in Q3 2018.
A 3-year average of $2.5 million and a median of $1.5 million in 2018 frame the typical range for Net Income.
The sharpest annual moves came in 2018 and 2019: Net Income jumped 614.38% in 2018, then plunged 83.77% in 2019.
Over 3 years, Net Income stood at $14.0 million in 2018, then tumbled by 98.59% to $197000.0 in 2019, then plunged by 282.23% to -$359000.0 in 2022.
According to Business Quant data, Net Income over the past three periods registered -$359000.0, $2.7 million, and $197000.0 for Q4 2022, Q3 2022, and Q2 2019 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Net Income (Qtr)
1	Vertex Pharmaceuticals	138.89 Bn	131.04 Bn	2.84 Bn	1.10 Bn
2	Regeneron Pharmaceuticals	86.05 Bn	78.06 Bn	3.93 Bn	1.30 Bn
3	Argenx Se	65.56 Bn	60.38 Bn	1.37 Bn	482.00 Mn
4	Moderna	55.46 Bn	50.32 Bn	52.00 Mn	-782.00 Mn
5	BeOne Medicines	42.12 Bn	37.02 Bn	1.53 Bn	237.01 Mn
6	Alnylam Pharmaceuticals	31.62 Bn	28.31 Bn	992.69 Mn	164.49 Mn
7	BioNTech SE	27.70 Bn	9.30 Bn	668.28 Mn	-355.03 Mn
8	Insmed	27.51 Bn	26.35 Bn	358.27 Mn	-13.27 Mn
9	Royalty Pharma	27.38 Bn	26.54 Bn	-	81.49 Mn
10	SciSparc	830,176.72	830,176.72	-	-

Download Data